Pomerantz Law Firm Investigates Geron Corporation for Potential Investor Misconduct

Overview

Pomerantz Law Firm is currently scrutinizing Geron Corporation (Geron or the Company) as part of an investigation aimed at safeguarding the interests of investors who may have been affected by potential misconduct. This inquiry arises from reports of disappointing financial outcomes and allegations of unlawful business practices involving securities fraud.

Background on Geron Corporation

Geron Corporation is a biopharmaceutical company focused on developing therapies for cancer and other serious diseases. With a commitment to groundbreaking research and innovative drug development, Geron has gained attention for its recently approved blood-disorder treatment, Rytelo. However, recent developments have raised significant concerns among the investor community.

Findings from the Recent Investigation

On February 26, 2025, Geron released its financial results for the fourth quarter and full year of 2024, which indicated a concerning trend. During an earnings call, executives revealed that the company had observed flat revenue trends for its drug Rytelo. This revelation created a ripple effect in the market, leading to a notable decline in Geron’s stock price immediately after the announcement.

These findings have prompted Pomerantz LLP to explore whether any officers or directors within the company may have engaged in actions that could be classified as securities fraud or other illegal business practices. Investors who believe they might be affected are being encouraged to step forward and share their experiences.

About Pomerantz LLP

Founded by the late Abraham L. Pomerantz, often referred to as the dean of the class action bar, Pomerantz LLP has a rich history in corporate and securities litigation. The firm stands out for its robust advocacy for investors' rights, specifically those impacted by securities fraud and corporate fraud. With more than 85 years in practice, the firm boasts a reputation for achieving multimillion-dollar settlements on behalf of their clients.

Next Steps for Involved Investors

Investors of Geron Corporation are urged to contact Pomerantz LLP’s Danielle Peyton for further inquiries or to discuss potential claims. The firm is dedicated to ensuring that any individuals potentially impacted are afforded the opportunity to join the ongoing investigation and protect their rights.

As this investigation unfolds, both current and prospective investors of Geron Corporation should remain vigilant regarding their investments and aware of the implications these findings may hold for the company’s future.

For those seeking to initiate a claim or gather more information, reaching out to Danielle Peyton via email or phone is highly advised. This will allow affected shareholders to understand their position and explore their options within the forthcoming legal framework surrounding this case.

Conclusion

As the situation at Geron develops, investors must stay keenly attuned to announcements and financial results that could impact the company's performance and stock viability. Pomerantz LLP’s inquiry underscores the critical role that investor protection plays in the landscape of corporate governance.

For continuous updates on this investigation, any reports released by Pomerantz LLP will be invaluable resources for investors as they navigate through this challenging phase.

For more details, you can visit Pomerantz LLP’s website or contact them directly for assistance.